利拉鲁肽 Liraglutide

Liraglutide is a fully FDA-approved GLP-1 receptor agonist that's been in clinical use since 2010 — making it one of the most extensively studied drugs in this class. It works by mimicking glucagon-like peptide-1, a hormone your gut releases after you eat, and it's approved for two distinct purposes: managing type 2 diabetes (as Victoza) and chronic weight management (as Saxenda at a higher dose).

If you're researching GLP-1 drugs, liraglutide is the baseline you compare everything else against. It's not the newest or the most potent option anymore, but it has a clinical track record that newer drugs are still building toward — years of real-world data, well-characterized side effects, and established cardiovascular outcomes data from the LEADER trial.

The 31-amino acid structure is a close analog of native human GLP-1, modified with a fatty acid chain that extends its half-life to roughly 13 hours,^[1] allowing once-daily dosing instead of the multiple daily injections required by earlier GLP-1 drugs.

• Liraglutide is FDA-approved as Victoza (type 2 diabetes) and Saxenda (weight management) — two brand names, two dose ceilings, one molecule.
• The SCALE Obesity trial showed approximately 8% mean body weight loss at 3.0 mg over 56 weeks, compared to roughly 2.6% with placebo.

The dose escalation schedule for liraglutide is slower and more gradual than you might expect. For weight management (Saxenda), you start at 0.6 mg daily for one week — a dose too low to produce meaningful weight loss, but designed to let your GI tract adjust. Each week, the dose increases by 0.6 mg until you reach the 3.0 mg maintenance dose at week five.^[2]

That escalation matters. Most of the nausea people experience with liraglutide is concentrated in the first four to six weeks. Patients who rush the escalation or skip straight to higher doses report significantly more GI distress.

For type 2 diabetes management (Victoza), the ceiling is lower: 1.8 mg daily. The starting dose is the same 0.6 mg, escalating to 1.2 mg after one week, then to 1.8 mg if additional glycemic control is needed.^[3] The weight loss effects at the diabetes dose are real but more modest than at the 3.0 mg weight management dose.

Liraglutide Dose Escalation — Saxenda (Weight Management)

If you can't tolerate 3.0 mg, the prescribing guidance allows staying at a lower dose — but the clinical trials showed meaningfully better outcomes at the full 3.0 mg target.^[2]

Liraglutide isn't the most potent GLP-1 drug available anymore, but it has something the newer drugs don't: a decade-plus of cardiovascular outcomes data. The LEADER trial — a large randomized trial in over 9,000 patients with type 2 diabetes and high cardiovascular risk — showed that liraglutide reduced the rate of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by a statistically significant margin compared to placebo.^[4] That data took years to generate, and it's the reason liraglutide remains a first-line option for diabetic patients with established cardiovascular disease.

The LEADER trial result

The LEADER trial (NCT01179048) enrolled 9,340 patients with type 2 diabetes and high cardiovascular risk. Liraglutide reduced the rate of major adverse cardiovascular events — the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke — by a statistically significant margin versus placebo over a median follow-up of 3.8 years.^[4] This was the first cardiovascular outcomes trial to demonstrate benefit for a GLP-1 receptor agonist.

The other thing liraglutide has is pediatric approval. Saxenda is approved for adolescents aged 12 and older with obesity — a population where treatment options are limited and where the evidence base for newer agents like semaglutide is still developing.^[2]

Your gut releases GLP-1 within minutes of eating. Under normal circumstances, GLP-1 is degraded by an enzyme called DPP-4 within one to two minutes — it's a fast-acting signal that barely has time to do its job. Liraglutide is a modified analog of that same 31-amino acid peptide, with a fatty acid side chain attached that binds to albumin in the bloodstream and dramatically slows its clearance. The result is a half-life of roughly 13 hours,^[1] which is why once-daily dosing works.

When liraglutide binds GLP-1 receptors in the pancreas, it triggers glucose-dependent insulin secretion — meaning it stimulates insulin release only when blood glucose is elevated. This is a meaningful safety advantage over older diabetes drugs that force insulin release regardless of blood sugar levels. At the same time, it suppresses glucagon (the hormone that tells your liver to release stored glucose), which further lowers blood sugar after meals.^[1]

The appetite and weight effects come from GLP-1 receptors in the hypothalamus and brainstem — areas of the brain that regulate hunger and satiety. Liraglutide signals "you've eaten enough" even when calorie intake is lower than usual. It also slows gastric emptying, which means food moves through your stomach more slowly and you feel full longer.^[3] These two mechanisms together — central appetite suppression and peripheral slowing of digestion — are what produce the caloric deficit that drives weight loss.

The pivotal weight loss trial for liraglutide 3.0 mg was the SCALE Obesity and Prediabetes trial (NCT01272219), a 56-week randomized controlled trial in adults with obesity or overweight plus at least one weight-related comorbidity. Participants on liraglutide 3.0 mg lost an average of approximately 8% of body weight, compared to roughly 2.6% in the placebo group — a net difference of about 5.4 percentage points.^[2] To put that in concrete terms: someone starting at 220 pounds would lose roughly 17-18 pounds on liraglutide versus about 6 pounds on placebo.

About 63% of liraglutide-treated participants lost at least 5% of body weight, and about 33% lost at least 10%.^[2] Those aren't uniform results — some patients respond much better than others, and the distribution is wide.

For type 2 diabetes, the evidence is extensive. A systematic review published in 2025 confirmed GLP-1 receptor agonists as a class reduce HbA1c (a 90-day average of blood glucose levels) meaningfully across multiple trials.^[5] Liraglutide at 1.8 mg daily typically reduces HbA1c by approximately 1.0–1.5 percentage points — a clinically meaningful reduction for most patients with type 2 diabetes.^[3]

The cardiovascular outcomes data from LEADER is the most clinically significant finding in liraglutide's history. In 9,340 high-risk patients followed for a median of 3.8 years, liraglutide demonstrated a statistically significant reduction in major adverse cardiovascular events versus placebo.^[4] This is the kind of hard endpoint data — not just surrogate markers — that changes prescribing guidelines.

What We Don't Know Yet

• Long-term weight maintenance — Most trials ran 56 weeks. Weight regain after stopping liraglutide is well-documented, and the long-term durability of weight loss with continuous use beyond two years is less characterized than with newer agents.
• Lean mass preservation — GLP-1 receptor agonists as a class cause some loss of fat-free mass alongside fat loss.^[6] The degree to which liraglutide specifically affects muscle mass versus fat mass, and whether resistance training modifies this, hasn't been fully characterized.
• Psychiatric adverse events — The European Medicines Agency investigated GLP-1 agonists including liraglutide following reports of suicidal ideation and other psychiatric adverse events in pharmacovigilance data.^[7] Causality hasn't been established, but this signal is being actively monitored.
• Adolescent long-term outcomes — Saxenda's pediatric approval is relatively recent, and long-term data on growth, development, and weight maintenance in adolescents is still accumulating.

During dose escalation (weeks 1–5):

• Nausea — The most commonly reported side effect across trials. Typically worst in the 24–48 hours after each dose increase and tends to improve as your body adjusts. Eating smaller meals and avoiding high-fat foods during escalation helps.
• Vomiting and diarrhea — Less common than nausea but reported, particularly at the 1.8 mg and 2.4 mg escalation steps.
• Decreased appetite — This one is often welcome, but it can be disorienting if it's more pronounced than expected. Some patients eat too little during early weeks and experience fatigue as a result.

At stable dose (3.0 mg for weight loss):

• Constipation — More common at maintenance doses than during escalation. Adequate hydration and fiber intake matter here.
• Injection site reactions — Mild redness, bruising, or tenderness at the injection site. Rotating sites — abdomen, thigh, upper arm — reduces this significantly.
• Fatigue — Reported by some patients, particularly in the first few weeks. Usually transient.

Rare but worth knowing:

• Pancreatitis — A class-level concern for all GLP-1 drugs. If you develop persistent, severe abdominal pain radiating to your back, stop the medication and seek care immediately.
• Gallbladder disease — Rapid weight loss of any kind increases gallstone risk. Liraglutide is no exception.
• Thyroid C-cell tumors — Liraglutide carries a boxed warning based on animal studies showing thyroid C-cell tumors in rodents. The relevance to humans is uncertain, but liraglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.^[3]
• Psychiatric adverse events — Reports of suicidal ideation and mood changes have been submitted to pharmacovigilance databases for GLP-1 drugs including liraglutide.^[7] Causality is unconfirmed, but if you notice significant mood changes, contact your prescriber.

If you experience severe abdominal pain, signs of an allergic reaction (rash, difficulty breathing, rapid heartbeat), or symptoms of low blood sugar when combining liraglutide with other diabetes medications, contact your provider the same day — don't wait for a scheduled appointment.

FDA approval status — as of 2026-03

Liraglutide is fully FDA-approved under two brand names: Victoza (liraglutide 1.2 mg and 1.8 mg) for adults with type 2 diabetes, and Saxenda (liraglutide 3.0 mg) for chronic weight management in adults with a BMI (body mass index) of 30 or greater, or 27 or greater with at least one weight-related condition. Saxenda is also approved for adolescents aged 12 and older with obesity. Both are available by prescription through licensed pharmacies in the United States.

Liraglutide is available through standard retail and specialty pharmacies with a valid prescription. It does not require a compounding pharmacy — you're getting an FDA-approved, commercially manufactured product with full quality controls.

Cost is a real consideration. Without insurance, Saxenda and Victoza are expensive; manufacturer savings programs (Novo Nordisk offers a savings card for eligible patients) can reduce out-of-pocket costs significantly. Insurance coverage for Saxenda specifically — the weight management indication — varies widely by plan and often requires prior authorization with documentation of comorbidities and prior weight loss attempts.

If cost or access is a barrier, ask your prescriber specifically about the Novo Nordisk patient assistance program, and confirm whether your insurance covers the weight management indication versus the diabetes indication before filling.

Liraglutide was the dominant GLP-1 option for weight management for several years, but the landscape shifted significantly with the approval of semaglutide (Wegovy, 2.4 mg weekly) and tirzepatide (Zepbound). The efficacy gap is real and worth understanding before you and your doctor make a treatment decision.

GLP-1 Class: Weight Loss Efficacy Comparison

The once-daily injection schedule is a practical disadvantage for liraglutide compared to the weekly injections required by semaglutide and tirzepatide — adherence is harder when you're injecting every day. That said, some patients and prescribers prefer liraglutide's longer track record, its established pediatric approval, or its cardiovascular outcomes data in diabetic patients specifically.

For a deeper look at how these drugs compare mechanistically and clinically, see our pages on semaglutide and tirzepatide.

• Efficacy ceiling — Liraglutide's ~8% mean weight loss is meaningful but roughly half what semaglutide achieves and less than half of tirzepatide's results. For patients who need substantial weight loss, this gap matters clinically.
• Daily injection burden — Once-daily subcutaneous injections are more demanding than once-weekly alternatives. Long-term adherence data reflects this.
• Lean mass loss — Like other GLP-1 drugs, liraglutide causes some reduction in fat-free mass alongside fat loss.^[6] The clinical significance of this — particularly for older patients or those with sarcopenia — isn't fully resolved.
• Thyroid C-cell tumor signal — The boxed warning is based on rodent data, and the human relevance is uncertain, but it creates a contraindication for a meaningful subset of patients.
• Psychiatric signal — The pharmacovigilance data on psychiatric adverse events is hypothesis-generating, not conclusive.^[7] But it's an open question that hasn't been fully answered.